BD&L Summit 2021
Attending this event?

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Tuesday, March 9

10:00am EST

Chairperson’s Opening Remarks
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, ELI LILLY

Tuesday March 9, 2021 10:00am - 10:10am EST

10:10am EST

PANEL DISCUSSION: Looking at the Big Picture: Deal Drivers and How Companies Determine Internally Whether to Go/No-Go a Deal
  • Who makes the decision internally – R&D, the Board, CEOs?
  • Making the difficult decision to kill and internal program in favor of a new product – what are the trade-offs?
  • Considering the rising importance of a product’s commercial versus clinical success when evaluating the target

avatar for Daniel B. Tumas, DVM, PhD, DACVP

Daniel B. Tumas, DVM, PhD, DACVP

Executive Director, Head of Search and Evaluation, Corporate Development, GILEAD SCIENCES, INC.
avatar for Adam Muzikant, Ph.D.

Adam Muzikant, Ph.D.

Chief Business Officer, FLEXION THERAPEUTICS
avatar for Rich Daly

Rich Daly

avatar for Michael Shih

Michael Shih

Head of Global Transactions, Sanofi Partnering, SANOFI
avatar for Jason Okazaki

Jason Okazaki

Chief Legal and Business Officer, ASSEMBLY BIOSCIENCES

Tuesday March 9, 2021 10:10am - 10:55am EST

11:00am EST

PANEL DISCUSSION: Establish an Integrated and Optimized BD&L Process
  • Identify strategies to get the most out of your team during the entire BD&L process
  • Outline how to systemize the search and evaluation, diligence, contracting process
  • Discuss when specific team members get involved while the roles of others taper down
  • Define roles, responsibilities and efforts of each function at various parts of the lifecycle

avatar for Niels Emmerich

Niels Emmerich

Vice President, Global Head Search & Evaluation, ABBVIE
avatar for Timothy Herpin

Timothy Herpin

Vice President Business Development, Infectious Diseases and Vaccines, JOHNSON & JOHNSON
avatar for Michael Flaschen

Michael Flaschen

Head of HQ Transactions,, MERCK

Tuesday March 9, 2021 11:00am - 11:45am EST

11:45am EST

Zoom Q&A
Tuesday March 9, 2021 11:45am - 12:15pm EST

12:15pm EST

PANEL DISCUSSION: Exploring Innovative Deal Constructs and Choosing the Right Partner and Deal Structure to Meet the Company’s Goals
  • Factors to take into consideration when selecting a partner
  • The power and potential pitfalls of deal champions
  • How do you decide what the “right” deal structure is for the collaboration?
  • Different structures, goals and valuations for early vs. late stage deals
  • Deciding whether to go the M&A route vs. alliances or product acquisition
  • Examples of innovative deal structures

avatar for Ioannis Sapountzis

Ioannis Sapountzis

Corporate SVP and Global Head BD&L, BOEHRINGER INGELHEIM
avatar for Martin Picard

Martin Picard

Head of External R&D, Global Research & Development, MERCK KGaA
avatar for Christopher Haskell

Christopher Haskell

Vice President and Head, Open Innovation Center - North America West, BAYER
avatar for Jeffrey Wade

Jeffrey Wade

Executive Vice President, Corporate and Administrative Affairs and CFO, LEXICON PHARMACEUTICALS, INC.

Tuesday March 9, 2021 12:15pm - 1:00pm EST

1:05pm EST

Designing a Co-Promote for Success: Effective Alliances in Joint Commercialization
  • Share considerations for assessing potential co-promote transactions
  • Profile prior co-promotes to spotlight key insights and implications
  • Uncover key design choices that drive both term sheet and operating agreement development
  • Maximize the value for both parties by balancing capabilities and long-term goals
  • Integrate design choices into the transaction process and resolve deadlocks via effective governance practices

avatar for Cody Powers

Cody Powers


Tuesday March 9, 2021 1:05pm - 1:35pm EST

1:35pm EST

2:15pm EST

Pharma-Academic Collaboration for Advancing Drug Discovery

Steven E. Cohen, M.D.

Executive Director, Search & Evaluation in Specialty Medicine, Global Business Development, Translational Medicine in Specialty Medicine & Cancer Enterprise, DAIICHI SANKYO, INC.

Tuesday March 9, 2021 2:15pm - 2:45pm EST

2:50pm EST

The VC Perspective: Deal Drivers, Trends for 2021 and Pitfalls that Can Derail the Deal
avatar for Brian Axe

Brian Axe


avatar for Luba Greenwood, J.D.

Luba Greenwood, J.D.

avatar for Jennifer Friel Goldstein

Jennifer Friel Goldstein

Managing Partner, Life Sciences & Healthcare, SVB Capital, SILICON VALLEY BANK
avatar for Alex Zisson

Alex Zisson

Managing Director, H.I.G. CAPITAL
avatar for John Gustofson

John Gustofson

Managing Director, ABBVIE VENTURES

Tuesday March 9, 2021 2:50pm - 3:35pm EST

3:35pm EST

Closing Remarks
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, ELI LILLY

Tuesday March 9, 2021 3:35pm - 3:45pm EST

3:45pm EST

Zoom Q&A
Tuesday March 9, 2021 3:45pm - 4:15pm EST
Wednesday, March 10

10:00am EST

Chairperson’s Opening Remarks
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, ELI LILLY

Wednesday March 10, 2021 10:00am - 10:15am EST

10:15am EST

Incorporate Market Access Assessments into your Diligence Process and Deal-Making Strategy

avatar for Catherine Angell Sohn, Pharm.D.

Catherine Angell Sohn, Pharm.D.

avatar for Adam Kundzewicz, Ph.D.

Adam Kundzewicz, Ph.D.

Global Head of Strategic Market Access Initiatives, BOEHRINGER INGELHEIM
avatar for Alex Santini

Alex Santini

Senior VP - Market Access Executive
avatar for Laura Randa

Laura Randa

Strategic Advisor and Member of the Advisory Board, TUTELA PHARMACEUTICALS and EMEDGENE

Wednesday March 10, 2021 10:15am - 11:00am EST

11:05am EST

Virtual Due Diligence – Perspectives on Leading Remotely
  • Why, how and when – the role of due diligence in deal making
  • Leading diligences through lockdown – what we’ve learned and how we’ve adapted
  • Leveraging a virtual data room to ease your workload

avatar for John Goodall, PhD.

John Goodall, PhD.

Due Diligence Director, Business Development Operations, ASTRAZENECA

Wednesday March 10, 2021 11:05am - 11:30am EST

11:35am EST

Post-Transaction Tactics to Enable Technical Transfer for Out-licensing and In-licensing Transactions
avatar for Selina Estwick

Selina Estwick

Manager- Lilly Research Labs, Technical Transfer & Due Diligence, ELI LILLY

Wednesday March 10, 2021 11:35am - 12:05pm EST

12:05pm EST

Zoom Q&A
Wednesday March 10, 2021 12:05pm - 12:35pm EST

12:35pm EST

PANEL DISCUSSION: Conducting a Thorough and Effective IP Due Diligence Review: Uncovering the IP Issues that can Derail the Deal
  • Understand what your IP team needs in order to conduct efficient diligence
  • Overview of the current status of IP law – what new areas to look out for
  • Conducting cost-effective FTO searches
  • Identifying any ownership conflicts or infringement risks
  • Extra-territoriality
  • Ways to address the IP problems to save the deal
  • Making your patent portfolio attractive to buyers
  • Patent term extensions and exclusivity analysis
  • Impact of the IP analysis on valuation

avatar for Forrester Liddle

Forrester Liddle

Senior Director of Transactions, Head of Intellectual Property, JOUNCE THERAPEUTICS, INC.
avatar for Olga Kay

Olga Kay

Senior IP Counsel, ROCHE MOLECULAR SYSTEMS (Diagnostics)
avatar for William Coppola

William Coppola

Intellectual Property Counsel, AERIE PHARMACEUTICALS

Wednesday March 10, 2021 12:35pm - 1:20pm EST

1:25pm EST

Getting the Most Out of Your Deal Decisions – Sharing Best Practices in After Action Reviews
Many folks associate After Action Reviews (AARs) with a negative emotional learning event.  IF that was the trigger, you can likely sympathize and share your own memories of these hand wringing series of discussions. Ultimately, the goal of an AAR is to try and understand what mitigations might be important to put in place in order to NEVER experience that kind of issue again!   However, the best practice for leveraging AAR as a tool is to do it routinely AND not just at the end of a project – during, shortly after the key milestone and long after the key milestone.   One needs to create a culture that supports open and objective assessments along with rigor of process to make the most out of everyone’s time.

avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, ELI LILLY

Wednesday March 10, 2021 1:25pm - 1:55pm EST

1:55pm EST

Zoom Q&A + Networking Breakout
Wednesday March 10, 2021 1:55pm - 2:25pm EST

2:25pm EST

PANEL DISCUSSION: Drafting and Negotiating Key Contract Terms to Minimize Future Risks
  • Working with the team to ensure that the terms included in the agreement can be executed
  • Tailoring the terms to the goals and type of the deal
  • Clearly defining the responsibilities of each party
  • Adapting critical contract terms based on the deal structure and to ensure the success of the alliance
    • Termination and force majeure clauses
    • Reps and Warranties
    • Governance
    • Milestones and reporting requirements
    • Indemnification

avatar for Chris Slavinsky

Chris Slavinsky

avatar for Ahmed Mousa

Ahmed Mousa

SVP Corporate Operations & General Counsel, PIERIS PHARMACEUTICALS
avatar for Ariel Jasie

Ariel Jasie

Chief Business Officer, General Counsel, & Corporate Secretary, eGENESIS, INC.

Wednesday March 10, 2021 2:25pm - 3:10pm EST

3:10pm EST

Closing Remarks and Close of Conference
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, ELI LILLY

Wednesday March 10, 2021 3:10pm - 3:20pm EST

3:20pm EST

Zoom Q&A
Wednesday March 10, 2021 3:20pm - 3:50pm EST